Compare RSSS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSSS | ELTX |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.9M | 63.3M |
| IPO Year | 2008 | 2014 |
| Metric | RSSS | ELTX |
|---|---|---|
| Price | $2.15 | $1.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $18.00 |
| AVG Volume (30 Days) | 44.9K | ★ 328.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 39.29 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $28,793,922.00 | $2,301,000.00 |
| Revenue This Year | $1.81 | N/A |
| Revenue Next Year | $5.73 | N/A |
| P/E Ratio | $23.11 | ★ N/A |
| Revenue Growth | ★ 2.77 | N/A |
| 52 Week Low | $1.92 | $1.71 |
| 52 Week High | $4.12 | $16.00 |
| Indicator | RSSS | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 29.02 |
| Support Level | $2.00 | N/A |
| Resistance Level | $2.36 | $3.32 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 57.14 | 26.87 |
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.